
Anastrol1 mg
Beacon Pharmaceuticals PLC
Anastrozole is a non-steroidal aromatase inhibitor indicated in postmenopausal women for hormone receptor (HR)-positive breast cancer.
Anastrozole is a non-steroidal aromatase inhibitor indicated in postmenopausal women for hormone receptor (HR)-positive breast cancer. Its established, evidence-based uses are:
Patients with estrogen receptor-negative disease, and those who did not previously respond to tamoxifen, are unlikely to respond to Anastrozole.
Anastrozole is not indicated in premenopausal women, because its mechanism of lowering estrogen depends on postmenopausal physiology (peripheral aromatization); it does not reliably suppress ovarian estrogen production. It is sometimes used off-label (unlicensed, based on limited evidence) for conditions such as pubertal gynecomastia in boys or fertility-related ovulation induction protocols, but efficacy and safety for these uses have not been established, and such use should occur only under specialist supervision.
| Indication | Adult Dose | Typical Duration |
|---|---|---|
| Adjuvant treatment of early breast cancer (postmenopausal, HR-positive) | 1 mg orally once daily | Commonly up to 5 years (based on major clinical trials), or as directed by the oncologist |
| Advanced/metastatic breast cancer, first-line | 1 mg orally once daily | Continued until disease progression is documented |
| Advanced breast cancer after tamoxifen failure | 1 mg orally once daily | Continued until disease progression is documented |
Tablets may be taken with or without food, at approximately the same time each day, to maintain consistent blood levels. If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose; doses should not be doubled.
No dosage adjustment is required in renal impairment or in the elderly. No adjustment is required in mild-to-moderate hepatic impairment; Anastrozole has not been formally studied in severe hepatic impairment, so it should be used with caution in that setting. See Use in Special Populations for details.
Adverse effects reported with Anastrozole in clinical trials, listed by frequency:
Patients should seek prompt medical attention for severe rash, swelling, breathing difficulty, chest pain, or yellowing of the skin/eyes.
Anastrozole is contraindicated in:
Anastrozole is also not indicated for use in premenopausal women, since its efficacy depends on the low-estrogen physiology of the postmenopausal state; use outside postmenopausal status is considered inappropriate rather than beneficial.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.